STAT+: Milestone Pharma’s nasal spray rapidly restores normal heart rhythm, achieving goal of key study

If approved, etripamil has the potential to be the first self-administered treatment for PSVT. Individuals with unresolved episodes now often receive more expensive care in emergency departments.

Milestone Pharmaceuticals said Monday that an experimental nasal-spray medicine acted quickly to treat people experiencing episodes of a rapid but non-fatal heart rate — more than doubling the conversion to normal heart rhythm and achieving the primary goal of a late-stage clinical trial.

The medicine, called etripamil, is meant to treat people with paroxysmal supraventricular tachycardia, or PSVT, a condition characterized by episodes of rapid heartbeat that suddenly start and stop. PSVT is not life threatening, but can be disruptive for people who experience its symptoms, which include palpitations, shortness of breath, lightheadedness, and anxiety, among others.

Continue to STAT+ to read the full story…